BioNTech (NASDAQ:BNTX) Given New $124.00 Price Target at JPMorgan Chase & Co.

BioNTech (NASDAQ:BNTX) had its price objective lowered by JPMorgan Chase & Co. from $125.00 to $124.00 in a report released on Monday, Benzinga reports. The firm currently has a neutral rating on the stock.

Other equities analysts have also issued research reports about the stock. TD Cowen boosted their target price on shares of BioNTech from $85.00 to $132.00 and gave the company a “hold” rating in a report on Monday, October 21st. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Bank of America lifted their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft increased their price target on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. Finally, HSBC lifted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $135.46.

BioNTech Stock Down 2.3 %

Shares of BNTX opened at $108.97 on Monday. The company has a market capitalization of $25.91 billion, a PE ratio of -48.22 and a beta of 0.26. The stock’s 50-day moving average price is $109.72 and its two-hundred day moving average price is $95.90. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.86) EPS. On average, analysts anticipate that BioNTech will post -2.93 EPS for the current year.

Institutional Trading of BioNTech

Hedge funds have recently bought and sold shares of the company. Covestor Ltd lifted its holdings in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. GAMMA Investing LLC lifted its stake in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Blue Trust Inc. grew its stake in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. Finally, Crewe Advisors LLC purchased a new position in shares of BioNTech in the first quarter worth about $75,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.